1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone | 709033-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone
• 英文别名: 1-[1-(2-Chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanone
• CAS: 709033-17-0
• 化学式: C₂₂H₂₁Cl₂N₃O₂
• 分子量: 430.334
• InChiKey: JBCFDMJWDPFMLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040122074A1

  公开（公告）日：2004-06-24

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein. 1

  本文描述了化合物公式（I），它们作为大麻素受体配体并在动物中治疗受大麻素受体拮抗剂调节的疾病、症状和/或疾病的用途。
• PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF
  申请人：Dow L. Robert

  公开号：US20070254935A1

  公开（公告）日：2007-11-01

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein.

  本文描述了公式(I)化合物作为大麻素受体配体并用于治疗动物中受大麻素受体拮抗剂调控的疾病、病况和/或失调的用途。
• Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
  申请人：Pfizer Inc

  公开号：US20040224962A1

  公开（公告）日：2004-11-11

  Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗肥胖、超重和强迫性暴饮暴食的药物组合物。这些药物组合物由烟碱受体部分激动剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。
• Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
  申请人：Pfizer Inc

  公开号：US20040224963A1

  公开（公告）日：2004-11-11

  Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗尼古丁依赖或成瘾、烟草依赖或成瘾、减轻尼古丁戒断症状或帮助戒烟或减少烟草使用或药物滥用或其他行为依赖的药物组合物。药物组合物由尼古丁受体部分激动剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。
• Pharmaceutical composition for the prevention and treatment of addiction in a mammal
  申请人：Coe Wadsworth Jotham

  公开号：US20050043327A1

  公开（公告）日：2005-02-24

  Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of alcohol use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compositions are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗酒精或可卡因依赖或成瘾、烟草依赖或成瘾、减轻酒精戒断症状或帮助停止或减轻酒精使用或药物滥用或包括赌博在内的其他行为依赖的药物组合物。药物组合物由阿片受体拮抗剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。